abacavir/lamivudine combination (Kivexa) (No. 175/05)

GlaxoSmithKline

Product Update

8 April, 2005

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Tablets delivering a fixed dose combination of abacavir 600mg and lamivudine 300mg are accepted for use in NHS Scotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults and adolescents over 12 years, in combination with other antiretroviral medicinal products. Both products are nucleoside reverse transcriptase inhibitors.

In patients for whom this combination is appropriate, it offers a single tablet at a lower cost per dose compared with the individual components.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including Wednesday, 9 February 2005.

Vice Chairman
Scottish Medicines Consortium

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6989
E-mail:rosie.murray@nhshealthquality.org

Chairman Professor David Webb